PO Box 11183
Ellerslie
Auckland, 1542
New Zealand

10th July 2024

Announcement: New lenalidomide brand funded. Wider access. New platform

Dear Healthcare Professional,

We are pleased to announce significant updates regarding the funding and access to lenalidomide. These changes aim to broaden access and improve treatment options for your patients.

Funding changes[1]

Effective from 1 August 2024:

- Lenalidomide Viatris will be funded in New Zealand for patients with
  - **plasma cell dyscrasia**
    - e.g., multiple myeloma, not including Waldenström macroglobulinaemia, requiring treatment; and
    - not refractory to prior lenalidomide use.
  - **myelodysplastic syndrome**
    - low or intermediate-1 risk myelodysplastic syndrome (based on IPSS or an IPSS-R score of less than 3.5) associated with a deletion 5q cytogenetic abnormality; and
    - have transfusion-dependent anaemia.
- Patients new to lenalidomide will start with Lenalidomide Viatris.
- Existing Revlimid® users will need to have transitioned to the Lenalidomide Viatris brand. Revlimid® will only be available through the Exceptional Circumstances Framework.

Effective from 1 February 2025:

- Lenalidomide Viatris will be the sole funded brand.

Pregnancy Prevention Program (PPP)

- Registration to the Viatris Care PPP as part of the risk management plan is mandatory prior to prescribing or dispensing Lenalidomide Viatris for all patients (men, childbearing and non-childbearing women).
- This program differs from the currently available one and accessible here: www.viatriscare.co.nz

Information for Healthcare Professionals

- Apply for a special authority number for eligible new patients
- Register with Viatris Care program via www.viatriscare.co.nz ***before prescribing or dispensing Lenalidomide Viatris***
    - Enrol to receive approval, have your registration number handy.
    - Receive educational information for yourself and your patient.
    - Complete consents and declarations
    - Generate a Prescription Authorisation Code (PAC) with every prescription.
    - Upon receiving script, pharmacist to order Lenalidomide Viatris after checking validity PAC and fulfilling requirements of the program.
- Initiate discussions with patients regarding the transition from Revlimid® to Lenalidomide Viatris by 31 January 2025.

Ordering Lenalidomide Viatris

- Only pharmacists who are registered on www.viatriscare.co.nz should order Lenalidomide Viatris.
- Lenalidomide Viatris is available to order via your preferred wholesaler.
- DO NOT place an order with the wholesaler unless you have verified that the PAC in the system is valid.

Pharmacode	Description	Pack Type/Size	PHARMAC Listing Price[1]
2673525	LENALIDOMIDE CAP 5MG 21BL AU/NZ VIA	21 Blister Pack	$ 76.92
2673533	LENALIDOMIDE CAP 10MG 21BL AU/NZ VIA	21 Blister Pack	$ 50.30
2673541	LENALIDOMIDE CAP 15MG 21BL AU/NZ VIA	21 Blister Pack	$ 62.13
2673568	LENALIDOMIDE CAP 25MG 21BL AU/NZ VIA	21 Blister Pack	$ 65.09

Contact Details

Reporting of suspected adverse events is important for the monitoring of the safety of all medicines. Any adverse events which are experienced with Lenalidomide Viatris should be reported by HCPs and/or patients to:

Centre for Adverse Reactions Monitoring (CARM)
via URL: https://pophealth.my.site.com/carmreportnz/s/ and/or

Viatris Care program
Email: admin@viatriscare.co.nz
Tel (free call): 0800 111 229.

1. Pharmaceutical Management Agency of New Zealand, Available from Decision to increase access to lenalidomide and pomalidomide through a brand change for lenalidomide - Pharmac | Te Pātaka Whaioranga | NZ Government Accessed July 2024.